Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears Medtox's drugs-of-abuse products:

This article was originally published in Clinica

Executive Summary

Medtox Diagnostics, a subsidiary of Medtox Scientific, has received US FDA 510(k) marketing clearance for its Profile-ER device and for 10 configurations of its Verdict-II product line. The Profile-ER is an on-site, drugs-of-abuse test that can screen for nine commonly abused drugs. The product, which is targeted at hospital laboratories for emergency response screening to patients who have taken a drug overdose, involves a one-step procedure and produces a qualitative result in seven minutes. The Verdict-II was developed for the prison, parole and rehabilitation markets and now consists of 13 different configurations to detect between one and five drugs-of-abuse, says the Burlington, North Carolina company.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT069897

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel